99 members · 99 US-listed
Best Gene/Cell Therapy stocks
−0.5%3-month median
- The Gene/Cell Therapy theme has 99 members; their median 3-month return is −0.5%, behind the S&P 500 (+4.7%).
- The 3-month leader is RGC (Regencell Bioscience Holdings L) at +92.2%.
- 46% of members trade above their 200-day average; analysts made 158 estimate raises and 147 cuts in 30 days.
Top 10 by 3-month return
Members ranked by price return. Stocks the batch flags for extreme price moves are left out.
| # | Stock | Market cap | 1M | 3M | 12M | Above 200-day |
|---|---|---|---|---|---|---|
| 1 | RGC Regencell Bioscience Holdings L · NASDAQ | $5.4B | +73.4% | +92.2% | −36.3% | No |
| 2 | ALVO Alvotech · NASDAQ | $1.8B | −12.2% | +61.3% | −40.3% | Yes |
| 3 | PRGO Perrigo Company plc · NYSE | $2.2B | +11.2% | +57.5% | −25.0% | Yes |
| 4 | ACB Aurora Cannabis Inc. · NASDAQ | $250,707,840 | −7.3% | +47.2% | −25.7% | Yes |
| 5 | BHC Bausch Health Companies Inc. · NYSE | $2.4B | +11.0% | +44.9% | +2.2% | Yes |
| 6 | IRD Opus Genetics, Inc. · NASDAQ | $342,350,784 | −20.3% | +40.9% | +107.8% | No |
| 7 | ANIK Anika Therapeutics Inc. · NASDAQ | $275,689,120 | −1.4% | +40.4% | +113.5% | Yes |
| 8 | PCRX Pacira BioSciences, Inc. · NASDAQ | $1.5B | +47.1% | +40.1% | +57.8% | Yes |
| 9 | AMPH Amphastar Pharmaceuticals, Inc. · NASDAQ | $1.1B | +7.7% | +38.8% | +10.4% | Yes |
| 10 | TEVA Teva Pharmaceutical Industries · NYSE | $47.4B | +2.8% | +30.3% | +109.2% | Yes |
How broad is the move
Share of members above their moving averages, and analyst estimate changes across the theme.
Above 50-day average37%
Above 200-day average46%
Estimate raises (30d) 158Estimate cuts (30d) 147
Theme median vs S&P 500
Track this theme every day
Hub ranks every member daily and alerts you when a leader breaks out or estimates turn.